Cystic Fibrosis Clinical Trial
Official title:
Effects of Endurance Training Intensity on Exercise Capacity, Body Composition, and Appetite Regulation in Cystic Fibrosis
| Verified date | June 2024 |
| Source | University of Kiel |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Aim of the randomized controlled trial is to investigate the effects of endurance training with different intensities on physical performance, body composition and appetite regulation in people with cystic fibrosis.
| Status | Active, not recruiting |
| Enrollment | 70 |
| Est. completion date | December 2024 |
| Est. primary completion date | December 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 70 Years |
| Eligibility | Inclusion Criteria: - confirmed diagnosis of cystic fibrosis by at least 2 sweat tests and / or by the presence of two CF mutations, - willingness to participate in and to comply with the research project procedure, - written informed consent of patients, - age = 18 years, - FEV1 of pred. = 40%, - Stable condition (as indicated by absence of one or more signs: new or increased haemoptysis, increased malaise, fatigue or lethargy, temperature over 38°C, weight loss, sinus pain and a decrease in pulmonary function by 10% or more) Exclusion Criteria: - Severe pulmonary exacerbation, - cor pulmonale, - musculoskeletal discomfort that makes a regular exercise training impossible, - untreated CF-related diabetes |
| Country | Name | City | State |
|---|---|---|---|
| Germany | Fachklink Satteldüne der DRV Nord | Nebel / Amrum | Schleswig-Holstein |
| Germany | Strandklinik St. Peter-Ording | Saint Peter-Ording | Schleswig-Holstein |
| Lead Sponsor | Collaborator |
|---|---|
| University of Kiel | Fachklinik Satteldüne der DRV Nord, Strandklinik St. Peter-Ording, University of Kiel, Arbeitsbereich Sportmedizin und Trainingswissenschaften |
Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | change in Peak Oxygen Uptake | measured with peak Oxygen uptake (VO2) in percent predicted | at baseline and after 4 weeks of exercise training program | |
| Primary | change in Peak Workload | measured with peak Workload in percent predicted | at baseline and after 4 weeks of exercise training program | |
| Primary | change body fat mass index | measured with body fat mass index (FMI) in kg / m*2 | at baseline and after 4 weeks of exercise training program | |
| Primary | change in Body fat free mass index | measured with fat free body mass index (FFMI) in kg / m*2 | at baseline and after 4 weeks of exercise training program | |
| Secondary | change in Forced Expiratory Volume in 1 second | measured with Forced Expiratory Volume in 1 second (FEV1) in percent predicted | at baseline and after 4 weeks of exercise training program | |
| Secondary | change in Health related quality of life | measured with the Cystic Fibrosis Questionnaire Revised (CFQ-R); 9 Quality of life domains: Physical, role/school, vitality, emotion, social, body image, eating, treatment burden, health perceptions: 3 symptom scales: Weight, respiratory, and digestion Scores range from 0 to 100, with higher scores indicating better health. | at baseline and six and twelve months after completion of exercise training program | |
| Secondary | appetite control - subjective feeling of hunger | measured with visual analogue scales. The scale consists of a 10 cm vertical line anchored with "not hungry at all" at the left side and with "extremely hungry" at the right side. | at baseline and after 4 weeks of exercise training program |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |